Related Experiment Video
Updated: Nov 3, 2025
Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses
Published on: November 24, 2014
An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic
Lynette M Phillips1,2, Shoudong Li1,2, Joy Gumin1,2
1Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Background:
Oncolytic adenoviruses are promising new treatments against solid tumors, particularly for glioblastoma (GBM), and preclinical models are required to evaluate the mechanisms of efficacy. However, due to the species selectivity of adenovirus, there is currently no single animal model that supports viral replication, tumor oncolysis, and a virus-mediated immune response. To address this gap, we took advantage of the Syrian hamster to develop the first intracranial glioma model that is both adenovirus replication-permissive and immunocompetent.
Methods:
We generated hamster glioma stem-like cells (hamGSCs) by transforming hamster neural stem cells with hTERT, simian virus 40 large T antigen, and h-RasV12. Using a guide-screw system, we generated an intracranial tumor model in the hamster. The efficacy of the oncolytic adenovirus Delta-24-RGD was assessed by survival studies, and tumor-infiltrating lymphocytes (TILs) were evaluated by flow cytometry.
Results:
In vitro, hamGSCs supported viral replication and were susceptible to Delta-24-RGD mediated cell death. In vivo, hamGSCs consistently developed into highly proliferative tumors resembling high-grade glioma. Flow cytometric analysis of hamster gliomas revealed significantly increased T-cell infiltration in Delta-24-RGD infected tumors, indicative of immune activation. Treating tumor-bearing hamsters with Delta-24-RGD led to significantly increased survival compared to hamsters treated with phosphate buffered saline (PBS).
Conclusions:
This adenovirus-permissive, immunocompetent hamster glioma model overcomes the limitations of previous model systems and provides a novel platform to study the interactions between tumor cells, the host immune system, and oncolytic adenoviral therapy; understanding of which will be critical to implementing oncolytic adenovirus in the clinic.
Insights
A new Syrian hamster glioma model allows oncolytic adenovirus replication and immune response, crucial for studying glioblastoma treatments. This model improves preclinical evaluation of oncolytic virotherapy efficacy.
Area of Science:
- Oncolytic virotherapy
- Cancer research
- Immunology
Background:
- Oncolytic adenoviruses show promise for solid tumors like glioblastoma (GBM).
- Existing animal models lack the ability to support viral replication, tumor oncolysis, and a virus-mediated immune response simultaneously.
- A species-selective limitation hinders comprehensive preclinical evaluation of adenovirus efficacy.
Purpose of the Study:
- To develop a novel intracranial glioma model in Syrian hamsters.
- To create a model that is both permissive to adenovirus replication and immunocompetent.
- To overcome limitations of current preclinical models for oncolytic adenovirus therapy.
Main Methods:
- Generated hamster glioma stem-like cells (hamGSCs) through cell transformation.
- Established an intracranial tumor model in hamsters using a guide-screw system.
- Assessed the efficacy of oncolytic adenovirus Delta-24-RGD via survival studies and flow cytometry for tumor-infiltrating lymphocytes (TILs).
Main Results:
- Hamster glioma stem-like cells supported in vitro viral replication and cell death upon Delta-24-RGD treatment.
- In vivo, tumors resembled high-grade glioma and showed increased T-cell infiltration after viral infection.
- Treatment with Delta-24-RGD significantly improved survival in tumor-bearing hamsters compared to PBS controls.
Conclusions:
- The developed hamster glioma model is adenovirus-permissive and immunocompetent, addressing key limitations of previous systems.
- This model offers a new platform for studying the interplay between tumor cells, the immune system, and oncolytic adenoviral therapy.
- Understanding these interactions is critical for advancing oncolytic adenovirus applications in clinical settings.
More Related Videos
06:12Production of Genetically Engineered Golden Syrian Hamsters by Pronuclear Injection of the CRISPR/Cas9 Complex
Published on: January 9, 2018
10:13Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice
Published on: August 12, 2014